Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating REL-1017 as an adjunctive treatment for major depressive disorder has been withdrawn. The sponsor is MGGM LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• REL-1017

Snippet

Sponsor: MGGM LLC | Conditions: Major Depressive Disorder (MDD) | Phase 3 | Status: WITHDRAWN